Project

Sequencing Aggressive Germline Prostate Cancer (CIP)

This project will search for genetic determinants of susceptibility to aggressive prostate carcinoma in Caucasians and African Americans. We will also sequence a representative subset of therapy-resistant tumors and produce a rich resource of coding SNPs for African Americans, a currently under-represented ethnic group in dbSNP.

Sequencing Aggressive Germline Prostate Cancer (CIP) Details

Center Initiated Projects (CIPs) are proposed by the McDonnell Genome Institute to help fulfill the mission and strategic vision of the NHGRI and NIH. All CIP data will be released in a timely manner via appropriate databases in accordance with NHGRI and NIH guidelines.

Project Summary: This proposal seeks to address four primary goals. First, our work will try to elucidate genetic determinants of susceptibility to aggressive prostate carcinoma. Second, we will attempt to identify the determinants with differential risk in Caucasians and African Americans. Third, from those patients who fail primary therapy for prostate cancer, we will select and sequence a representative subset of tumors using whole genome methods. Fourth, we will produce a rich resource of coding SNPs for African Americans, a currently under-represented ethnic group in dbSNP. Status of Samples: 48 of 600 samples in house for exome sequencing (300 cases and 300 controls) 48 control samples in resource bank 0 of 50 samples (tumor genomes) in house for whole genome sequencing Pending work: Exome sequencing of 600 samples Whole genome sequencing of 50 tumor samples Follow-up work includes validation and extension sequencing. Collaborators: Dr. Adam Kibel. IRB Status: Compliant.